Skip to content

Kim Pc Kuypers

3 papers in the library · 57 citations · publishing 2020-2025

Papers

Mephedrone and Alcohol Interactions in Humans

Frontiers in Pharmacology January 28, 2020 Esther Papaseit, Clara Pérez-mañá, Elizabeth B. de Sousa Fernandes Perna et al. 27 citations

Combining mephedrone with alcohol amplifies cardiovascular effects and intensifies euphoria and well-being compared to either drug alone, while mephedrone reduces the sedative effects of alcohol. In a double-blind, placebo-controlled trial with 11 male volunteers, the combination increased blood pressure, heart rate, and subjective feelings of euphoria. Mephedrone alone and alcohol alone were also tested. The results suggest that the abuse liability of mephedrone is greater when taken with alcohol, similar to other psychostimulants like amphetamines and MDMA.

Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey.

Br J Pain July 14, 2022 Valerie Bonnelle, Will J Smith, Natasha L Mason et al. 26 citations

A survey of chronic pain sufferers who have used classical psychedelics reports that both macrodoses and microdoses are associated with pain relief. Among respondents, 78% reported pain reduction after macrodosing, and 55% reported pain reduction after microdosing. The findings suggest that psychedelics may have analgesic potential in this population, though the survey design cannot establish causation.

Low to moderate doses of 3-methylmethcathinone (3-MMC) produce analgesic effects in healthy volunteers: a proof of principle study with a designer drug

Psychopharmacology April 30, 2025 Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason et al. 4 citations

Low to moderate doses of 3-methylmethcathinone (3-MMC) produce prolonged, dose-related analgesic effects in healthy volunteers. In a cross-over, placebo-controlled study with 14 participants, doses of 25, 50, and 100 mg elevated pressure pain threshold and reduced subjective painfulness and unpleasantness in both pressure pain threshold and cold pressor test paradigms. The analgesic effects were most prominent after 50 and 100 mg and persisted for up to 5 hours after dosing. 3-MMC also produced dose-related mood improvements at 1 hour but not at 5 hours. The findings suggest that doses low enough to avoid challenging subjective experiences and associated with a benign side effect profile may be sufficient for analgesia.